Meriofert Pfs

Luteinising hormone (human), Follicle‑Stimulating Hormone, the active ingredient in Meriofert Pfs, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is employed in fertility treatment to stimulate ovarian follicular development and luteal steroidogenesis in women with anovulation, hypogonadotropic hypogonadism, or undergoing assisted reproductive technologies.

GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Pfs is a gonadotropin used in reproductive medicine to support ovarian function. - Infertility due to anovulation: promotes follicular growth to enable ovulation. - Hypogonadotropic hypogonadism: replaces deficient LH and FSH to restore normal reproductive hormone production. - Controlled ovarian stimulation for assisted reproductive technologies: provides precise hormonal stimulation to optimize oocyte retrieval for IVF or ICSI cycles.

Adverse reactions to Meriofert Pfs may vary in frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Local erythema: redness around the injection area. - Headache: transient headache episodes. - Nausea: mild gastrointestinal upset. - Abdominal discomfort: mild pelvic pain or bloating. - Mild ovarian hyperstimulation syndrome: mild fluid shift without severe complications.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: marked fluid accumulation, electrolyte imbalance, and organ dysfunction. - Multiple pregnancy: increased risk of twins or higher‑order gestations. - Thromboembolic events: rare blood clot formation. - Anaphylactic reaction: severe allergic response requiring immediate medical attention.

When prescribing Meriofert Pfs, clinicians should observe several precautionary measures. - Patient selection: evaluate for ovarian cysts, uncontrolled thyroid disease, or active malignancy before initiating therapy. - Monitoring: perform serial ultrasound and serum estradiol assessments to detect excessive ovarian response. - Dose adjustment: tailor the amount based on age, ovarian reserve, and response to prior stimulation cycles. - Pregnancy testing: confirm a negative pregnancy test prior to the first dose. - Drug interactions: review concomitant medications that may alter gonadotropin efficacy or increase risk of complications. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Pfs may interact with other medicines, requiring attention to avoid or monitor effects.

Major Interactions (Avoid): - GnRH agonists: concurrent use can cause excessive ovarian stimulation. - Estrogen‑containing oral contraceptives: antagonize the intended gonadotropin effect. - High‑dose hCG: increases risk of severe ovarian hyperstimulation syndrome.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for increased bleeding at injection sites. - Thyroid hormone therapy: may modify hormonal response and require dose adjustments. - Corticosteroids: can affect ovarian responsiveness and should be monitored.